1Data Platform Improves Human and Animal Lives

person with dog

1Data enables researchers to access datasets that aids in their pursuit of human and animal health medical advances.

Researchers at Kansas State University and the University of Missouri-Kansas City are curating big data to save human and animal lives and improve the quality of life for both.

The collaboration, called 1Data, standardizes and adds preclinical human and animal health research results into a data clearinghouse. Through the 1Data platform, researchers around the world use that data to:

  • Analyze data across animal species and even look at how the genetic information from a specific animal compares to a human.
  • Identify similarities in diseases, such as cancers and chronic mitral valve disease, that affect people and pets.
  • Develop and test new human and companion animal therapeutics, drugs and medical technologies.
  • Identify what drugs are likely to fail during clinical testing and at what phase, which saves time and money.

JCERT funding supports animal health and food safety-related research and academic programs at K-State Olathe.

“With the 1Data platform, researchers can access a diverse dataset to aid them in their pursuit of medical advances,” said Gerald Wyckoff, director of 1Data and professor of molecular biology and biochemistry at the University of Missouri-Kansas City and K-State Olathe.

Wyckoff leads 1Data with Majid Jaberi-Douraki , associate professor of mathematics with the K-State Institute of Computational Comparative Medicine, and Jim Riviere, professor emeritus with the K-State College of Veterinary Medicine. Multiple graduate students and postdoctoral researchers at both universities are involved.

The 1Data team is partnering with Elanco, which provides historic data from its clinical studies on dogs and cats.

In October 2019, researchers published two articles in peer-reviewed scientific journals that looked at how novel sharing data agreements – such as the one with Elanco – will accelerate medical breakthroughs and help reduce and mitigate drug-associated adverse events.

The team is using the data for specific projects that:

  • Research orphan diseases – which affect fewer than 200,000 people nationwide – and their approved therapies and test those against models generated on the 1Data platform.
  • Test a beta version of DrugAssist, a platform for precision and individualized medicine that computes demographic information about patients with breast cancer or Type 2 diabetes. The platform helps physicians tailor therapeutic drugs for patients; development of a similar platform for veterinarians is underway.
  • Use health data collected by wearable devices on veterans with PTSD, or post-traumatic stress disorder, and their service animals to find how frequently and effectively the service animals are at interventions.